nach oben

Drugs

Erschienen in:

01.06.2006 | Adis Drug Profile

Methylphenidate Transdermal System

In Attention-Deficit Hyperactivity Disorder in Children

verfasst von: Vanessa R. Anderson, Lesley J. Scott

Erschienen in: Drugs | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Abstract

▴ The methylphenidate transdermal system (MTS) patch is approved by the US FDA for use in children aged 6–12 years with attention-deficit hyperactivity disorder (ADHD). This delivery system permits sustained absorption of the drug through the skin and into the bloodstream. Methylphenidate (MPH) is a CNS agent thought to act on dopamine and noradrenaline (norepinephrine) pathways and thereby blocks the reuptake of these neurotransmitters into the presynaptic neuron.
▴ In children with ADHD, MTS patches releasing MPH doses of 10–30mg over a 9-hour period (12.5–37.5cm₂ patch size) is steadily absorbed, with mean peak plasma concentrations of d-MPH (20–46.5 ng/mL) reached in ≊8 hours.
▴ In well controlled trials in children with ADHD, patients administered MTS patches releasing MPH 10–30mg over ≊9 hours showed significantly greater improvements in their ADHD symptoms than placebo recipients.
▴ MTS patches are generally well tolerated in paediatric patients with ADHD, with treatment-emergent events being similar in nature to those reported with oral MPH. The majority of adverse events were mild to moderate in intensity.

Daytrana is a trademark of Shire Pharmaceuticals Ireland Limited. The use of trade names is for product identification purposes only and does not imply endorsement.

DOT Matrix is a trademark of Noven Pharmaceuticals, Inc.

OROS® is a trademark of ALZA Corporation.

American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics 2000; 105: 1158–70CrossRef

Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 1998; 59 Suppl. 7: 42–9PubMed

Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999 May; 38(5): 503–12PubMedCrossRef

Noven Pharmaceuticals Inc. Noven’s DOT Matrix® technology [online]. Available from URL: http://www.noven.com/research.htm [Accessed 2005 Dec 19]

Shire Pharmaceuticals Ireland Limited. Daytrana™ (methylphenidate transdermal system) [online]. Available from URL: http://www.daytrana.com [Accessed 2006 Apr 7]

Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999 Dec; 37(6): 457–70PubMedCrossRef

Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40(10): 753–72PubMedCrossRef

Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002 Nov; 22(8): 1107–31

Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin® LA). Drugs 2002; 62(15): 2251–9PubMedCrossRef

10.

Novartis. Ritalin LA® (methylphenidate hydrochloride) extended-release capsules: prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com [Accessed 2006 May 26]

11.

Pelham WE, Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jun; 44(6): 522–9PubMedCrossRef

12.

American Academy of Pediatrics. National institute of mental health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113: 762–9CrossRef

13.

Data on file. Shire, 2006 Feb 10

14.

Wigal SB, Pierce DM, Dixon CM, et al. Pharmacokinetics of methylphenidate transdermal system in children with ADHD [poster no. 207]. 18th Annual U.S. Psychiatric and Mental Health Congress; 2005 Nov 7–10; Las Vegas (NV)

15.

Gonzalez MA. Methylphenidate pharmacokinetics after dosing with a once-daily transdermal system [abstract no. 57A]. 48th Annual Meeting American Academy of Child and Adolescent Psychiatry; 2001 Oct 23–28; Honolulu (HI), 97

16.

Duchin K, Campbell DA, Linares E. Pharmacokinetics of multiple doses of methylphenidate transdermal system in children with attention deficit hyperactivity disorder [poster]. 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2002 Oct 22–27; San Francisco (CA)

17.

McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006 Feb; 9(3): 476–85PubMedCrossRef

18.

Melmed R, Findling RL, Lopez FA. The effects of transdermal methylphenidate with reference to OROS methylphenidate in ADHD [poster no. 205]. 18th Annual U.S. Psychiatric and Mental Health Congress; 2005 Nov 7–10; Las Vegas (NV)

19.

Greenhill LL, Pelham W, Lopez F, et al. Once-daily transdermal methylphenidate improves teacher, parent, and CGI-I ratings [abstract no. A27 plus poster]. 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2002 Oct 22–27; San Francisco (CA), 93–4

20.

Pelham WE, Burrows-MacLean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 2005 May; 13(2): 111–26PubMedCrossRef

21.

Noven Pharmaceuticals I. Safety summary. NDA NO: 21-514 [online]. Available from URL: http://www.fda.gov [Accessed 2006 May 19]

Titel: Methylphenidate Transdermal System
In Attention-Deficit Hyperactivity Disorder in Children
verfasst von: Vanessa R. Anderson
Lesley J. Scott
Publikationsdatum: 01.06.2006
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 8/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666080-00007

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2006

Treating Ocular Hypertension to Reduce Glaucoma Risk

Methylphenidate Transdermal System In Attention-Deficit Hyperactivity Disorder in Children

Antimicrobial Agents in Orthopaedic Surgery

Irritable Bowel Syndrome

Cytotoxic Chemotherapy for Pancreatic Cancer

Methylphenidate Transdermal System In Attention-Deficit Hyperactivity Disorder in Children